Table 2 Followed up data after discharge of the two groups.

From: Clinical features and prognostic risk factors of different sex with acute exacerbations of chronic obstructive pulmonary disease

 

Male group (n = 280)

Female group (n = 72)

p value*

Inhalation use

 Unused

54 (19.4%)

18 (25.4%)

0.284

 LAMA

18 (6.5%)

7 (9.9%)

0.332

 LABA/ICS

77 (27.7%)

29 (40.8%)

0.035

 LAMA/LABA

33 (11.9%)

6 (8.5%)

0.405

 LABA/LAMA/ICS

96 (34.5%)

11 (15.5%)

0.002

Followed up after discharge

 30d readmission rate

22 (8.3%)

6 (8.96%)

0.863

 90d readmission rate

43 (16.23%)

14 (20.9%)

0.365

 180d readmission rate

66 (24.91%)

15 (22.39%)

0.668

 180d death rate

17 (6.42%)

2 (2.99%)

0.406

 Compound results of readmission and mortality

77 (29.06%)

15 (22.39%)

0.276

  1. LABA long-acting beta-agonist, LAMA long-acting muscarinic antagonist, ICS inhaled corticosteroids. *Bold values indicate statistical significance (P＜0.05)
Back to article page